{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:00:14Z","timestamp":1784908814631,"version":"3.55.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.berh.2018.12.002","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T02:19:16Z","timestamp":1553134756000},"page":"453-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis"],"prefix":"10.1016","volume":"32","author":[{"given":"Anthony","family":"So","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Davies","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib3","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib5","first-page":"446","article-title":"Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients","volume":"66","author":"Fourni\u00e9","year":"1999","journal-title":"Rev Rhum Engl Educ"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/1529-0131(199906)42:6<1080::AID-ANR2>3.0.CO;2-7","article-title":"Psoriatic arthritis: a unified concept twenty years on","volume":"42","author":"McGonagle","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2018.12.002_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.semarthrit.2004.05.001","article-title":"A\u00a0comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis","volume":"34","author":"Taylor","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/S0021-9258(18)89560-6","article-title":"Human tumor necrosis factor. Production, purification, and characterization","volume":"260","author":"Aggarwal","year":"1985","journal-title":"J\u00a0Biol Chem"},{"issue":"11","key":"10.1016\/j.berh.2018.12.002_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1753-4887.1988.tb05376.x","article-title":"J\u00a0Natl Cancer Inst, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance","volume":"46","author":"O'Malley","year":"1988","journal-title":"Nutr Rev"},{"issue":"9","key":"10.1016\/j.berh.2018.12.002_bib11","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.berh.2018.12.002_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1025319031417","article-title":"Receptor-mediated choreography of life and death","volume":"23","author":"Bhardwaj","year":"2003","journal-title":"J\u00a0Clin Immunol"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(03)00490-8","article-title":"Regulation of proliferation, survival and apoptosis by members of the TNF superfamily","volume":"66","author":"Gaur","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-\u03baB: a key role in inflammatory diseases","volume":"107","author":"Tak","year":"2001","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nri910","article-title":"NF-kappaB regulation in the immune system","volume":"2","author":"Li","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.berh.2018.12.002_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.berh.2018.12.002_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1396-0296.2004.04044.x","article-title":"Infliximab","volume":"17","author":"Winterfield","year":"2004","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.12.002_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","article-title":"Pharmacokinetics and safety of golimumab, a fully human anti-TNF-\u03b1 monoclonal antibody, in subjects with rheumatoid arthritis","volume":"47","author":"Zhou","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-0378(97)00068-5","article-title":"Human placental Fc receptors and the transmission of antibodies from mother to fetus","volume":"37","author":"Simister","year":"1997","journal-title":"J\u00a0Reprod Immunol"},{"issue":"3","key":"10.1016\/j.berh.2018.12.002_bib21","first-page":"286","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.12.002_bib23","first-page":"5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J\u00a0Immunol Baltim Md 1950"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/1074-7613(95)90070-5","article-title":"Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor","volume":"3","author":"Yao","year":"1995","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor superfamily","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.berh.2018.12.002_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2018.12.002_bib27","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.berh.2018.12.002_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1074-7613(03)00296-6","article-title":"The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses","volume":"19","author":"Trinchieri","year":"2003","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.berh.2018.12.002_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"issue":"6029","key":"10.1016\/j.berh.2018.12.002_bib32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.berh.2018.12.002_bib33","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/ker192","article-title":"New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors","volume":"50","author":"Bonilla-Hern\u00e1n","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib34","article-title":"TNFa-inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"9","author":"Scotti","year":"2017","journal-title":"Clinical Pharmacist"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of rheumatology\/spondylitis association of America\/spondyloarthritis research and treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.12.002_bib37","first-page":"2286","article-title":"A\u00a0new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib39","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.12.002_bib40","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2018.12.002_bib41","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib42","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"01","key":"10.1016\/j.berh.2018.12.002_bib43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.12.002_bib44","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"van Denderen","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"9313","key":"10.1016\/j.berh.2018.12.002_bib47","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib49","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","article-title":"Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2018.12.002_bib52","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2018.12.002_bib53","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.12.002_bib54","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib55","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib56","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","article-title":"Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial","volume":"41","author":"Song","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/rheumatology\/keu263","article-title":"Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial","volume":"54","author":"Song","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib58","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"7","key":"10.1016\/j.berh.2018.12.002_bib59","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib60","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/acr.23276","article-title":"Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, placebo-controlled study","volume":"69","author":"Dougados","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.berh.2018.12.002_bib61","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib62","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib63","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib64","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/art.38776","article-title":"The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment Network and the assessment of SpondyloArthritis international society in response to the US Food and drug administration's comments and concerns","volume":"66","author":"Deodhar","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib65","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"10142","key":"10.1016\/j.berh.2018.12.002_bib66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.berh.2018.12.002_bib67","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib68","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study","volume":"74","author":"Deodhar","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib69","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A\u00a0randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9906","key":"10.1016\/j.berh.2018.12.002_bib71","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"26","key":"10.1016\/j.berh.2018.12.002_bib72","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.12.002_bib73","unstructured":"A study to evaluate the efficacy and safety of ustekinumab in the treatment of anti-TNF\u03b1 naive participants with active radiographic axial spondyloarthritis - full text view - ClinicalTrials.gov [internet]. [cited 2019 Mar 8]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02437162."},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib75","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib76","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/art.22531","article-title":"The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients","volume":"57","author":"Leeb","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib77","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib78","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib79","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10012","key":"10.1016\/j.berh.2018.12.002_bib80","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.berh.2018.12.002_bib81","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"3","key":"10.1016\/j.berh.2018.12.002_bib82","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2018.12.002_bib83","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3899\/jrheum.140876","article-title":"Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review","volume":"41","author":"Felquer","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib84","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2018.12.002_bib85","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis","volume":"135","author":"Nast","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.berh.2018.12.002_bib86","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.berh.2018.12.002_bib87","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.berh.2018.12.002_bib88","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2018.12.002_bib89","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib90","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.berh.2018.12.002_bib91","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1517\/13543784.2015.1035432","article-title":"Inflammatory bowel disease therapies discontinued between 2009 and 2014","volume":"24","author":"Mozaffari","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib92","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.berh.2016.07.005","article-title":"Advancements in the management of uveitis","volume":"30","author":"Schwartzman","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2018.12.002_bib93","unstructured":"103795s5503lbl.pdf [Internet]. [cited 2018 Jul 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf*FDA label for etanercept."},{"issue":"9227","key":"10.1016\/j.berh.2018.12.002_bib94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet Lond Engl"},{"issue":"7","key":"10.1016\/j.berh.2018.12.002_bib95","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib96","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib97","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib98","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib99","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.12.002_bib100","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib101","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2018.12.002_bib102","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib103","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","article-title":"Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions","volume":"69","author":"van den Bosch","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib104","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2018.12.002_bib105","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib107","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","article-title":"Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol","volume":"73","author":"van der Heijde","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.12.002_bib108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.berh.2018.12.002_bib109","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9999","key":"10.1016\/j.berh.2018.12.002_bib110","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.berh.2018.12.002_bib111","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"10.1016\/j.berh.2018.12.002_bib112","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"issue":"9894","key":"10.1016\/j.berh.2018.12.002_bib113","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.berh.2018.12.002_bib114","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2018.12.002_bib115","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"16","key":"10.1016\/j.berh.2018.12.002_bib116","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.berh.2018.12.002_bib117","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:19:03Z","timestamp":1761499143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":117,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1521694219300038"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.12.002","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}